Incyte skin disease cream for children meets main goal in late-stage
study
Send a link to a friend
[July 12, 2023]
(Reuters) -Incyte Corp said on Tuesday its cream to treat a type
of skin condition in children between the age of two to twelve met the
primary goal in a late-stage study, sending the company's shares up 4%
in after-market trading.
Opzelura showed statistically significant improvement in the chronic
skin condition, atopic dermatitis, on a disease severity scale compared
to patients treated with non-medicated cream.
Atopic dermatitis causes inflammation and irritation of skin. It affects
about 30% of the U.S. population, mostly children and adolescents,
according to the National Institute of Allergy and Infectious Diseases.
[to top of second column]
|
![](http://archives.lincolndailynews.com/2023/Jul/12/images/ads/current/peasley_lda_051513.png) The company said the safety of the
Opzelura was consistent with previous data, while longer term safety
study will continue as planned.
Opzelura is already approved as a treatment for skin conditions,
vitiligo and mild to moderate atopic dermatitis in patients 12 years
of age and older.
(Reporting by Khushi Mandowara in Bengaluru; Editing by Shailesh
Kuber)
[© 2023 Thomson Reuters. All rights
reserved.]This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content. |